

# David I Quinn Mbbs

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3070957/david-i-quinn-mbbs-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

329  
papers

13,632  
citations

57  
h-index

112  
g-index

367  
ext. papers

16,508  
ext. citations

5.2  
avg, IF

6  
L-index

#	Paper	IF	Citations
329	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> , 40, 12.e13-12.e22	2.8	1
328	Reply by Authors.. <i>Journal of Urology</i> , <b>2022</b> , 207, 313	2.5	
327	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.. <i>Journal of Urology</i> , <b>2022</b> , 207, 302-313	2.5	0
326	Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 516-516	2.2	
325	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.9	2
324	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102517	2.2	0
323	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 61-68	6.2	12
322	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1391-1398	12.9	7
321	Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1967-1973	12.9	4
320	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 812-820	4.3	4
319	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 683-694	59.2	73
318	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2020</b> , 35, 485-489	3.9	0
317	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa003	4.6	1
316	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1807-1814	4.3	2
315	EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 152967	3.4	
314	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , <b>2020</b> , 126, 2935-2937	6.4	
313	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. <i>Theranostics</i> , <b>2020</b> , 10, 3254-3262	12.1	6

312	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , <b>2020</b> , 126, 2597-2606	6.4	24
311	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 517-526	6.2	48
310	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 486-493	6.2	2
309	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e473-e477	3.3	0
308	Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2845-2854	7.5	5
307	Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence. <i>Trials</i> , <b>2020</b> , 21, 167	2.8	4
306	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 351-360.e3	3.3	6
305	Editorial Comment. <i>Journal of Urology</i> , <b>2020</b> , 203, 336-337	2.5	
304	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , <b>2020</b> , 78, 916-924	10.2	6
303	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 839-853	5.2	6
302	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1797-1806	2.2	56
301	p53 nuclear accumulation as an early indicator of lethal prostate cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 578-583	8.7	3
300	A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 755-762	4.3	10
299	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 241-247.e1	3.3	8
298	Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7
297	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1524-1530	8.9	14
296	Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 50-60	4	8
295	Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2682-2688	2.2	4

294	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , <b>2019</b> , 125, 3853-3863	6.4	3
293	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , <b>2019</b> , 16, 745-756	5.5	34
292	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , <b>2019</b> , 125, 4172-4180	6.4	34
291	Multiparametric liquid biopsy analysis in metastatic prostate cancer. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	33
290	Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2572-2572	2.2	7
289	Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4504-4504	2.2	15
288	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4510-4510	2.2	3
287	Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4573-4573	2.2	2
286	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5035-5035	2.2	4
285	Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 186-186	2.2	2
284	Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 377-377	2.2	14
283	A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 517-517	2.2	4
282	Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 222-222	2.2	
281	EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 275-275	2.2	
280	Association of next generation sequencing characteristics of MIBC specimens with clinical outcomes: The USC experience.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 397-397	2.2	
279	Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e16587-e16587	2.2	
278	PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5021-5021	2.2	
277	Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4563-4563	2.2	1

276	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 403-410	2.2	56
275	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7381-7387	12.9	9
274	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) <b>2019</b> , 7, 354		100
273	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 1-11	2.8	7
272	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 95-105	4	12
271	A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 172-178	1.9	64
270	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. <i>Future Oncology</i> , <b>2018</b> , 14, 527-536	3.6	
269	Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e719-e727	3.3	3
268	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , <b>2018</b> , 554, 189-194	50.4	388
267	A Universal Standard for the Validation of Blood Pressure Measuring Devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. <i>Hypertension</i> , <b>2018</b> , 71, 368-374	8.5	143
266	Training early childcare providers in evidence-based nutrition strategies can help improve nutrition policies and practices of early childcare centres serving racially and ethnically diverse children from low-income families. <i>Public Health Nutrition</i> , <b>2018</b> , 21, 1212-1221	3.3	4
265	Controlled molecular self-assembly of complex three-dimensional structures in soft materials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 70-74	11.5	17
264	Conductive gelatin methacrylate-poly(aniline) hydrogel for cell encapsulation. <i>Biomedical Physics and Engineering Express</i> , <b>2018</b> , 4, 015005	1.5	11
263	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4662-4671	12.9	15
262	Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers <b>2018</b> ,		2
261	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4599-TPS4599	2.2	11
260	Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 246-246	2.2	7
259	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 410-410	2.2	16

258	Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 431-431	2.2	4
257	P53 as a predictor of clinical outcome in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 57-57	2.2	4
256	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS712-TPS712	2.2	4
255	Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 274-274	2.2	2
254	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 624-624	2.2	
253	CT-based texture characterization of lymphadenopathy in urothelial carcinoma: Prediction of treatment response.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 514-514	2.2	
252	Novel method for rapid enrichment of high purity circulating tumor cells (CTCs) for prostate cancer (PCa) gene expression profiling.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 271-271	2.2	
251	Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 422-422	2.2	
250	P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS574-TPS574	2.2	
249	Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5027-5027	2.2	
248	Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1498-1504	2.2	24
247	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1579-1587	2.2	68
246	Differential growth and shape formation in plant organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 12359-12364	11.5	31
245	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , <b>2018</b> , 74, 611-620	10.2	49
244	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. <i>Clinical Biomechanics</i> , <b>2018</b> , 56, 61-69	2.2	5
243	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with Alterations. <i>Cancer Discovery</i> , <b>2018</b> , 8, 812-821	24.4	145
242	Comparative effectiveness of screening strategies for colorectal cancer. <i>Cancer</i> , <b>2017</b> , 123, 1516-1527	6.4	29
241	Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 339-351	3.5	2

240	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1015-1026	59.2	1788
239	Formation and size distribution of self-assembled vesicles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 2910-2915	11.5	78
238	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 635-641	3.3	3
237	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 459.e15-459.e24	2.8	2
236	Urethral Cancer <b>2017</b> , 54-67		
235	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , <b>2017</b> , 389, 67-76	40	1171
234	Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors. <i>Journal of Immigrant and Minority Health</i> , <b>2017</b> , 19, 1281-1289	2.2	7
233	Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. <i>BJU International</i> , <b>2017</b> , 120, 401-408	5.6	15
232	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7199-7208	12.9	57
231	Appropriate Use Criteria for F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 2026-2037	8.9	57
230	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9
229	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	8
228	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. <i>Cancer</i> , <b>2017</b> , 123, 4566-4573	6.4	24
227	Isolation of exosomes from whole blood by integrating acoustics and microfluidics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 10584-10589	11.5	405
226	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 742-749	3.3	18
225	Mining Human Mobility to Quantify Performance Status <b>2017</b> ,		3
224	Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study <b>2017</b> ,		19
223	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4501-4501	2.2	14

222	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4530-4530	2.2	5
221	Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 143-143	2.2	1
220	Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 192-192	2.2	1
219	Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 223-223	2.2	1
218	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 466-477	0.6	3
217	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 543-551	0.6	4
216	Habitat segregation and population structure of Caribbean sea anemones and associated crustaceans on coral reefs at Akumal Bay, Mexico. <i>Bulletin of Marine Science</i> , <b>2017</b> , 93, 1025-1047	1.3	6
215	Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 465-465	2.2	
214	Comparative effectiveness of initiating colorectal cancer (CRC) screening (Scr) at age 45.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 531-531	2.2	1
213	Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 167-167	2.2	1
212	Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 163-163	2.2	
211	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4592-TPS4592	2.2	
210	Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5019-5019	2.2	
209	Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5046-5046	2.2	
208	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5023-5023	2.2	1
207	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). <i>Journal of Patient-Reported Outcomes</i> , <b>2017</b> , 2, 27	2.6	9
206	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. <i>Future Oncology</i> , <b>2016</b> , 12, 2689-2699	3.6	4
205	Fabrication of conductive gelatin methacrylate-polyaniline hydrogels. <i>Acta Biomaterialia</i> , <b>2016</b> , 33, 122-30.8	3.8	64



204	Finite domination and Novikov rings. Laurent polynomial rings in several variables. <i>Journal of Pure and Applied Algebra</i> , <b>2016</b> , 220, 2648-2682	0.6	
203	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1500-9	2.2	65
202	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1652-9	2.2	217
201	Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11516-11516	2.2	4
200	Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4513-4513	2.2	10
199	Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4517-4517	2.2	17
198	Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16121-e16121	2.2	1
197	A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4581-TPS4581	2.2	1
196	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA4500-LBA4500	2.2	13
195	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 355-355	2.2	28
194	Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer: USC trial 4B-10-4.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 424-424	2.2	4
193	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose Interleukin 2 in renal cell carcinoma patients (CTEP#7870).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 500-500 <sup>2,2</sup>	2.2	1
192	Sipuleucel-T (sip-T)Induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 165-165	2.2	1
191	Randomized phase I/II trial of two schedules of bortezomib and bevacizumab (BBmibmab) in metastatic renal cell cancer: USC trial 4K-05-1.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 574-574	2.2	
190	Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 522-522	2.2	
189	Baseline GFR and cisplatin-induced renal toxicity in urothelial cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 380-380	2.2	
188	The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 241-241 <sup>2,2</sup>	2.2	
187	Sipuleucel-T (sip-T)Induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23116-e23116	2.2	

186	Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5077-5077	2.2	
185	FOBT compared to FIT in reducing colorectal cancer (CRC) incidence.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e18119-e18119	2.2	
184	The opportunity cost (OC) of low adherence with screening (scr) recommendations for colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1553-1553	2.2	
183	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5079-5079	2.2	
182	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16001-e16001	2.2	
181	Targeted next generation sequencing (NGS) of matched primary tumor, metastasis, circulating tumor cells (CTCs), and cell-free DNA (cfDNA) in a patient with advanced prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23057-e23057	2.2	
180	The opportunity cost (OC) of performing radical prostatectomy (RP) by low volume (LV) providers (Prov).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6509-6509	2.2	
179	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16004-e16004	2.2	
178	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4560-4560	2.2	
177	Comparative effectiveness of CT colonography (CT-C) as a screening (Scr) tool for colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e13049-e13049	2.2	
176	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 5825-5837	4.4	20
175	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , <b>2016</b> , 76, 597-608	4.2	13
174	Safety and feasibility of fasting in combination with platinum-based chemotherapy. <i>BMC Cancer</i> , <b>2016</b> , 16, 360	4.8	103
173	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma <b>2016</b> , 4, 81		37
172	Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 450-456.e1	3.3	3
171	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2478-83	2.2	25
170	What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 6S-12S	8.9	10
169	Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. <i>Radiology</i> , <b>2015</b> , 274, 624-5	20.5	14

168	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2015</b> , 30, 195-9	3.9	29
167	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1601-8	2.2	38
166	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 426-35	21.7	209
165	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 897-907	3.5	24
164	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , <b>2015</b> , 10, 45-53	5	34
163	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2392-8	10.3	22
162	Trauma care and education. <i>Clinical Teacher</i> , <b>2015</b> , 12, 291-291	1.1	
161	Rapid changes in circulating tumor cells following anti-angiogenic therapy. <i>Convergent Science Physical Oncology</i> , <b>2015</b> , 1, 015002		3
160	Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. <i>Journal of Urology</i> , <b>2015</b> , 194, 378-85	2.5	104
159	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 245-60	2.8	33
158	Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1856-62	7.5	35
157	Finite domination and Novikov rings: Laurent polynomial rings in two variables. <i>Journal of Algebra and Its Applications</i> , <b>2015</b> , 14, 1550055	0.4	1
156	Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4504-4504	2.2	6
155	Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5040-5040	2.2	2
154	Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5066-5066	2.2	2
153	Emerging Agents in Renal Cell Carcinoma <b>2015</b> , 385-402		
152	Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 181-181	2.2	
151	Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 29-29	2.2	

150	Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4542-4542	2.2	
149	Colonoscopy versus less invasive approaches for colorectal cancer (CRC) screening (Scr): A strategic perspective.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6523-6523	2.2	
148	Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2538-2538	2.2	
147	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16092-e16092	2.2	
146	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study <b>2014</b> , 2, 2		33
145	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 3145-52	7.5	82
144	Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju013 <sup>9-7</sup>		33
143	Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1136-42	2.2	229
142	Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e55-8	3.3	1
141	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 52.e1-9	2.8	42
140	Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. <i>Urology</i> , <b>2014</b> , 83, 159-65	1.6	20
139	Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. <i>Cell Stem Cell</i> , <b>2014</b> , 14, 810-23	18	249
138	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 637-44	2.8	41
137	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. <i>BMC Cancer</i> , <b>2014</b> , 14, 966	4.8	20
136	Chromoplexy and hypoxic microenvironment drives prostate cancer. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1419-1421	21.7	1
135	Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6277-83	12.9	33
134	Skate park injury: a new mechanism of sternoclavicular joint dislocation. <i>EMA - Emergency Medicine Australasia</i> , <b>2014</b> , 26, 316-7	1.5	1
133	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , <b>2014</b> , 120, 2684-93	6.4	79

132	Oscillometric blood pressure: a review for clinicians. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 930-8		115
131	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 1227-34	3.5	7
130	Novel tyrosine kinase inhibitors for renal cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 67-73	3.8	6
129	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 51-61	3.5	1
128	International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4507-4507	2.2	1
127	Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4541-4541	2.2	2
126	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5002-5002	2.2	6
125	SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5006-5006	2.2	0
124	A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e16071 <sup>2</sup> -e16071 <sup>1</sup>	2.2	4
123	Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naïve metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5108-TPS5108	2.2	1
122	NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 296-296	2.2	5
121	Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 364-364	2.2	4
120	The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. <i>PLoS ONE</i> , <b>2014</b> , 9, e105326	3.7	16
119	SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5102-TPS5102	2.2	
118	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4595 <sup>2</sup> -TPS4595 <sup>1</sup>	2.2	1
117	Identification of biologic and inflammatory markers for predicting clinical responses to sipuleucel-T in CRPC.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 134-134	2.2	
116	Clinical and biologic factors for immune response to sipuleucel-T (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 219-219	2.2	
115	Prostatectomy at high- versus low-volume centers: A decision analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 175-175	2.2	

114	AXIN2 and prostate cancer recurrence after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 145-145	2.2	
113	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1016-22	4.3	38
112	Differentiating mTOR inhibitors in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 709-19	14.4	68
111	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. <i>European Urology</i> , <b>2013</b> , 63, 58-66	10.2	133
110	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. <i>Lancet Oncology</i> , <b>2013</b> , 14, 893-900	21.7	123
109	Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 416-22	3.3	5
108	Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1737-43	2.8	48
107	Warfarin ridge: an unusual location of benign papillary fibroelastoma. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1213	15.1	4
106	Intermittent versus continuous androgen deprivation in prostate cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1314-25	59.2	364
105	Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 1195-201	8.9	92
104	FINITE DOMINATION AND NOVIKOV RINGS. ITERATIVE APPROACH. <i>Glasgow Mathematical Journal</i> , <b>2013</b> , 55, 145-160	0.4	3
103	Targeted $\alpha$ -particle therapy of bone metastases in prostate cancer. <i>Clinical Nuclear Medicine</i> , <b>2013</b> , 38, 966-71	1.7	38
102	Crisis managers but not conflict resolvers: Mediating ethnic intrastate conflict in Africa. <i>Conflict Management and Peace Science</i> , <b>2013</b> , 30, 387-406	0.9	21
101	Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 131-61	2.2	35
100	Tivozanib in the treatment of renal cell carcinoma. <i>Biologics: Targets and Therapy</i> , <b>2013</b> , 7, 139-48	4.4	14
99	HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 292-292	2.2	3
98	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 336-336	2.2	4
97	Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 40-40	2.2	1

96	THE INCIDENCE ALGEBRA OF POSETS AND ACYCLIC CATEGORIES. <i>Kyushu Journal of Mathematics</i> , <b>2013</b> , 67, 117-127	0.3	
95	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. <i>BJU International</i> , <b>2012</b> , 109, 846-54	5.6	82
94	953 SIPULEUCEL-T IN AFRICAN AMERICANS: A SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS OF SIPULEUCEL-T IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , <b>2012</b> , 187,	2.5	2
93	Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1055-62	21.7	88
92	Small cell bladder cancer: biology and management. <i>Seminars in Oncology</i> , <b>2012</b> , 39, 615-8	5.5	9
91	"The Wizard of Oz:" a depiction of TBI-related neurobehavioral syndromes. <i>Academic Psychiatry</i> , <b>2012</b> , 36, 340-4	1.1	1
90	Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 526-37	6.1	34
89	Immune response to sipuleucel-T in prostate cancer. <i>Cancers</i> , <b>2012</b> , 4, 420-41	6.6	9
88	Blood cells and their use in active immunotherapy of prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , <b>2012</b> , 8, 528-33	4.4	4
87	Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2509-15	2.2	154
86	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 507-12	2.2	151
85	Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 637-43	1.7	104
84	Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4-4	2.2	16
83	Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 298-298	2.2	2
82	Sipuleucel-T product characterization across different disease states of prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 42-42	2.2	6
81	Emerging Agents in Renal Cell Carcinoma <b>2012</b> , 285-301		
80	Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. <i>Maturitas</i> , <b>2011</b> , 69, 296-303	5	26
79	Show us a sign: the search for "game changing" prostate cancer biomarkers. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 204-6	21.7	3

78	FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. <i>Clinical Nuclear Medicine</i> , <b>2011</b> , 36, 961-2	1.7	10
77	One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. <i>Psychiatric Services</i> , <b>2011</b> , 62, 162-70	3.3	68
76	Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 27-31	2.7	6
75	A phase II trial of gefitinib and pegylated IFN $\beta$ in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , <b>2011</b> , 16, 494-9	4.2	9
74	Experience with sorafenib and adverse event management. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 78, 24-32	7	49
73	Using molecular markers to help predict who will fail after radical prostatectomy. <i>Prostate Cancer</i> , <b>2011</b> , 2011, 290160	1.9	10
72	Biophysics of malarial parasite exit from infected erythrocytes. <i>PLoS ONE</i> , <b>2011</b> , 6, e20869	3.7	65
71	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. <i>Nature Medicine</i> , <b>2010</b> , 16, 324-8	50.5	191
70	Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3028-34	12.9	154
69	First light adaptive optics systems and components for the Thirty Meter Telescope <b>2010</b> ,		4
68	Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. <i>Urology</i> , <b>2010</b> , 76, 923-6	1.6	81
67	Cabazitaxel in prostate cancer: stretching a string. <i>Lancet, The</i> , <b>2010</b> , 376, 1119-20	4.0	10
66	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 825-35	3.5	13
65	Fasting and cancer treatment in humans: A case series report. <i>Aging</i> , <b>2009</b> , 1, 988-1007	5.6	228
64	COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. <i>Therapeutic Advances in Medical Oncology</i> , <b>2009</b> , 1, 69-77	5.4	2
63	Targeted therapy in renal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2009</b> , 1, 183-205	5.4	13
62	Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5788-93	2.2	90
61	Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, 43-50	3.3	24



60	Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. <i>World Journal of Urology</i> , <b>2009</b> , 27, 39-44	4	8
59	Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 199-209	6.2	30
58	A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 179-84	2.4	75
57	Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. <i>BJU International</i> , <b>2008</b> , 102, 1086-91	5.6	10
56	A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. <i>BJU International</i> , <b>2008</b> , 102, 1601-6	5.6	32
55	Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. <i>Journal of Urology</i> , <b>2008</b> , 180, 2384-8; discussion 2388	2.5	45
54	Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4488-96	2.2	198
53	A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 689-94	3.5	24
52	Creative approaches to staff development: global education in ITE in The Gambia. <i>Education 3-13</i> , <b>2007</b> , 35, 117-131	0.5	
51	Pain management, supportive and palliative care in patients with renal cell carcinoma. <i>BJU International</i> , <b>2007</b> , 99, 1305-12	5.6	12
50	The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. <i>Clinical Genitourinary Cancer</i> , <b>2007</b> , 5, 433-7	3.3	78
49	Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. <i>General Hospital Psychiatry</i> , <b>2007</b> , 29, 223-31	5.6	39
48	Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2007</b> , 133, 705-11	4.9	13
47	Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , <b>2006</b> , 106, 2624-9	6.4	31
46	Power Play: Mediation in Symmetric and Asymmetric International Crises. <i>International Interactions</i> , <b>2006</b> , 32, 441-470	0.5	41
45	Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1712-9	2.2	55
44	A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1556-63	12.9	56
43	Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. <i>Journal of Urology</i> , <b>2006</b> , 175, 1245-52	2.5	104

42	Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1420-4	9.7	76
41	Urethral Cancer <b>2006</b> , 27-37		1
40	Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 79-83	4.3	2
39	Far-Infrared/Submillimeter Astronomical Interferometry with Spaceborne Tether Formations. <i>Astrophysics and Space Science</i> , <b>2006</b> , 302, 225-239	1.6	12
38	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 126-134	8.9	25
37	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 126-34	8.9	11
36	The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. <i>Urologic Clinics of North America</i> , <b>2005</b> , 32, 217-30, vii	2.9	6
35	Molecular markers of prostate cancer outcome. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 858-87	7.5	153
34	Cytokine therapy: a standard of care for metastatic renal cell carcinoma?. <i>Clinical Genitourinary Cancer</i> , <b>2005</b> , 4, 181-6	3.3	29
33	Molecular prognostic factors in bladder cancer. <i>BJU International</i> , <b>2005</b> , 95, 739-42	5.6	11
32	EphB4 expression and biological significance in prostate cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 4623-32	10.1	115
31	Postchemotherapy residual masses in advanced seminoma: current management and outcomes. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 869-74	3.5	16
30	Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1105-13	6.1	30
29	Up-regulation of EphB4 in mesothelioma and its biological significance. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4305-15	12.9	38
28	Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. <i>Cancer</i> , <b>2004</b> , 100, 2627-36	6.4	103
27	Microscopic and gross extravesical extension in pathological staging of bladder cancer. <i>Journal of Urology</i> , <b>2004</b> , 171, 640-5	2.5	54
26	Is year of radical prostatectomy a predictor of outcome in prostate cancer?. <i>Journal of Urology</i> , <b>2004</b> , 171, 692-6	2.5	27
25	Angiogenesis-targeted therapies in prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 165-73		25

24	The future in advanced prostate cancer: take your partners or is the last dance for me?. <i>Reviews in Urology</i> , <b>2004</b> , 6 Suppl 10, S29-44	1	1
23	The mediating effects of effort upon the relationship between head injury severity and cognitive functioning. <i>Brain Injury</i> , <b>2003</b> , 17, 377-87	2.1	29
22	Characteristics of Early-Winter Caribou, Rangifer tarandus caribou, Feeding Sites in the Southern Purcell Mountains, British Columbia. <i>Canadian Field-Naturalist</i> , <b>2003</b> , 117, 352	0.8	5
21	Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. <i>Cancer</i> , <b>2003</b> , 97, 1884-93	6.4	75
20	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. <i>Cancer</i> , <b>2003</b> , 98, 955-61	6.4	44
19	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. <i>Oncogene</i> , <b>2003</b> , 22, 6005-12	9.2	86
18	A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. <i>Journal of Urology</i> , <b>2003</b> , 170, 1798-803	2.5	308
17	Mediating International Crises: Cross-National and Experimental Perspectives. <i>Journal of Conflict Resolution</i> , <b>2003</b> , 47, 279-301	2.2	60
16	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 3410-5	11.5	363
15	Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. <i>Cancer Research</i> , <b>2003</b> , 63, 4196-203	10.1	166
14	Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 951-6	2.2	95
13	Surgery and adjunctive chemotherapy for invasive bladder cancer. <i>Surgical Oncology</i> , <b>2002</b> , 11, 55-63	2.5	30
12	International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3206-12	2.2	182
11	Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3692-705	2.2	68
10	Acute renal impairment after immersion and near-drowning. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 382-6	12.7	22
9	An audit of oestrogen implant hormone replacement therapy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>1998</b> , 38, 455-60	1.7	5
8	Dissecting the rugby tackle: do shoulder pads contribute to cervical spine injuries?. <i>Medical Journal of Australia</i> , <b>1998</b> , 169, 501-2	4	2
7	Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. <i>Clinical Pharmacokinetics</i> , <b>1997</b> , 33, 344-400	6.2	63

6	Tinea of the skin, hair and nails. <i>Medical Journal of Australia</i> , <b>1996</b> , 165, 350-1	4	
5	Non-steroidal anti-inflammatory drugs. <i>Medical Journal of Australia</i> , <b>1995</b> , 163, 155-8	4	12
4	Radionuclide hepatobiliary scanning in patients with AIDS-related sclerosing cholangitis. <i>Clinical Nuclear Medicine</i> , <b>1993</b> , 18, 417-22	1.7	8
3	Defective interhemispheric integration and anomalous language lateralization in children at risk for schizophrenia. <i>Journal of Nervous and Mental Disease</i> , <b>1986</b> , 174, 418-27	1.8	29
2	Towards the cloning of the calf prochymosin gene. <i>Biochemical Society Transactions</i> , <b>1984</b> , 12, 487-488	5.1	1
1	Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer 284-294		